Biofilm-penetrant delivery systems for DNA-based antibiotics active against lung pathogens (MORRISU16MRC)
Applications are invited for a 4-year MRC Industrial CASE PhD studentship to work on a multidisciplinary collaborative project between Dr Chris Morris and Procarta Biosystems Ltd (www.procartabio.com).
Cystic fibrosis (CF) is a genetic disease that results in the production of highly viscous mucus in the respiratory tract. In the CF lung opportunistic pathogens such as Pseudomonas aeruginosa are inefficiently cleared from the airways and they form biofilm structures that are refractory to antibiotic treatment.
The aim of this fully-funded 4-year PhD studentship is to develop a drug delivery system for a DNA-based antibiotic that penetrates though the mucus and bacterial biofilm matrices that are found within the lung of cystic fibrosis patients.
This PhD project brings together academic expertise in pulmonary macromolecule delivery with the novel antibiotic technology for treating antibiotic resistant bacteria developed by Procarta. The successful candidate will be jointly supervised by Dr Chris Morris at UEA and Prof. Michael McArthur at Procarta Biosystems. The student will receive extensive multidisciplinary training from both academic and industrial teams.
Please direct informal enquiries to Dr Chris Morris ([email protected]
The studentship will commence in January 2017.
This 4 year PhD studentship is an MRC Industrial CASE Studentship in partnership with Procarta Biosciences Ltd. An annual stipend of £14,296 (plus a CASE top-up of £2500 per annum) is available to the successful candidate who meets the UK Research Council eligibility criteria: http://www.rcuk.ac.uk/funding/eligibilityforrcs/ . In most cases UK and EU nationals who have been ordinarily resident in the UK for 3 years prior to the start of the course are eligible for a full-award. Other EU nationals may qualify for a fees only award
i) Morris et al 2013 Antimicrob. Agents. Chemother. doi: 10.1128/AAC.06335-11
ii) Morris et al 2011 J. Cont. Rel. doi: 10.1016/j.jconrel.2010.12.003
iii) Zhou et al. 2014 Adv Drug Deliv Rev. http://dx.doi.org/10.1016/j.addr.2014.10.022
iv) McArthur & Bibb 2007 PNAS doi: 10.1073/pnas.0710724105